Umesh Chaudhari

6.0k total citations · 4 hit papers
46 papers, 4.3k citations indexed

About

Umesh Chaudhari is a scholar working on Immunology, Surgery and Molecular Biology. According to data from OpenAlex, Umesh Chaudhari has authored 46 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 14 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in Umesh Chaudhari's work include Lipoproteins and Cardiovascular Health (11 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Pluripotent Stem Cells Research (7 papers). Umesh Chaudhari is often cited by papers focused on Lipoproteins and Cardiovascular Health (11 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Pluripotent Stem Cells Research (7 papers). Umesh Chaudhari collaborates with scholars based in United States, United Kingdom and France. Umesh Chaudhari's co-authors include Robert Pordy, Christelle Lorenzato, Jennifer G. Robinson, Michel Farnier, John J.P. Kastelein, A.B. Gottlieb, Baker Dg, L T Dooley, Gisle Langslet and Mahfouz El Shahawy and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Umesh Chaudhari

44 papers receiving 4.2k citations

Hit Papers

Efficacy and Safety of Alirocumab in ... 2001 2026 2009 2017 2015 2001 2015 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
    2015 1.7k citations Jennifer G. Robinson, Michel Farnier et al. New England Journal of Medicine profile →
  2. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
    2001 707 citations Umesh Chaudhari et al. profile →
  3. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
    2015 316 citations Christopher P. Cannon, Bertrand Cariou et al. profile →
  4. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
    2015 291 citations Dean J. Kereiakes, Jennifer G. Robinson et al. American Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Umesh Chaudhari United States 25 2.4k 1.3k 1.2k 592 550 46 4.3k
Michael A. Bolognese United States 39 2.1k 0.9× 345 0.3× 646 0.6× 213 0.4× 511 0.9× 70 8.6k
Bernd Hohenstein Germany 26 722 0.3× 650 0.5× 106 0.1× 362 0.6× 321 0.6× 87 3.1k
Peter Wijngaard United States 21 2.9k 1.2× 593 0.5× 740 0.6× 814 1.4× 781 1.4× 46 4.9k
Agneta Siegbahn Sweden 39 1.2k 0.5× 668 0.5× 92 0.1× 3.9k 6.6× 311 0.6× 131 6.0k
Marlys L. Koschinsky Canada 53 6.1k 2.5× 1.8k 1.4× 341 0.3× 2.5k 4.2× 1.9k 3.4× 190 9.4k
Michael B. Boffa Canada 34 2.2k 0.9× 544 0.4× 147 0.1× 1.1k 1.9× 691 1.3× 100 4.2k
Marina Camera Italy 33 1.1k 0.5× 695 0.5× 44 0.0× 1.1k 1.8× 243 0.4× 108 3.9k
Eduardo Mysler United States 32 411 0.2× 2.0k 1.5× 260 0.2× 402 0.7× 38 0.1× 106 5.8k
Joep C. Defesche Netherlands 38 4.7k 1.9× 368 0.3× 709 0.6× 1.3k 2.3× 2.0k 3.6× 128 5.9k
Biao Xu China 35 967 0.4× 384 0.3× 119 0.1× 1.2k 2.1× 377 0.7× 176 4.3k

Countries citing papers authored by Umesh Chaudhari

Since Specialization
Citations

This map shows the geographic impact of Umesh Chaudhari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Umesh Chaudhari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Umesh Chaudhari more than expected).

Fields of papers citing papers by Umesh Chaudhari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Umesh Chaudhari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Umesh Chaudhari. The network helps show where Umesh Chaudhari may publish in the future.

Co-authorship network of co-authors of Umesh Chaudhari

This figure shows the co-authorship network connecting the top 25 collaborators of Umesh Chaudhari. A scholar is included among the top collaborators of Umesh Chaudhari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Umesh Chaudhari. Umesh Chaudhari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Santacroce, Giovanni, Umesh Chaudhari, Rocío del Amor, et al.. (2025). P0556 A novel switching of artificial intelligence to generate simultaneously multimodal images to assess inflammation and predict outcomes in Ulcerative Colitis. Journal of Crohn s and Colitis. 19(Supplement_1). i1122–i1123. 1 indexed citations
2.
3.
Jang, Jun‐Ho, Raymond Wong, Jonathan Weyne, et al.. (2023). P775: LONG-TERM EFFICACY AND SAFETY OF POZELIMAB MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. HemaSphere. 7(S3). e4357016–e4357016. 2 indexed citations
4.
Morton, Laura T., Umesh Chaudhari, Dennis F.G. Remst, et al.. (2023). Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential. Molecular Therapy — Methods & Clinical Development. 28. 249–261. 7 indexed citations
5.
Chaudhari, Umesh, et al.. (2023). Genome-wide profiling of miRNA-gene regulatory networks in mouse postnatal heart development—implications for cardiac regeneration. Frontiers in Cardiovascular Medicine. 10. 1148618–1148618. 2 indexed citations
6.
Nemade, Harshal, Umesh Chaudhari, Filomain Nguemo, et al.. (2020). Cyclooxygenases Inhibitors Efficiently Induce Cardiomyogenesis in Human Pluripotent Stem Cells. Cells. 9(3). 554–554. 9 indexed citations
7.
Shahawy, Mahfouz El, Christopher P. Cannon, Dirk Blom, et al.. (2017). Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). The American Journal of Cardiology. 120(6). 931–939. 23 indexed citations
8.
Rawekar, Alka, et al.. (2017). Utility of Low Fidelity Manikins for Learning High Quality Chest Compressions. The Indian Journal of Pediatrics. 85(3). 184–188. 2 indexed citations
9.
Chaudhari, Umesh, James K. Ellis, Vilas Wagh, et al.. (2017). Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes. Amino Acids. 49(12). 1955–1963. 29 indexed citations
10.
Chaudhari, Umesh, Harshal Nemade, P. Sureshkumar, et al.. (2017). Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Archives of Toxicology. 92(1). 371–381. 31 indexed citations
11.
Kastelein, John J.P., G. Kees Hovingh, Gisle Langslet, et al.. (2016). Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 11(1). 195–203.e4. 56 indexed citations
12.
Jones, Peter H., Harold Bays, Umesh Chaudhari, et al.. (2016). Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. The American Journal of Cardiology. 118(12). 1805–1811. 73 indexed citations
13.
Robinson, J.C., Michel Farnier, Umesh Chaudhari, et al.. (2015). ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB. Journal of the American College of Cardiology. 65(10). A1350–A1350. 6 indexed citations
14.
Jones, Peter H., Harold Bays, Umesh Chaudhari, et al.. (2015). POOLED SAFETY AND ADVERSE EVENTS IN NINE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 AND 3 CLINICAL TRIALS OF ALIROCUMAB. Journal of the American College of Cardiology. 65(10). A1363–A1363. 7 indexed citations
15.
Robinson, Jennifer G., Michel Farnier, Michel Krempf, et al.. (2015). Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine. 372(16). 1489–1499. 1683 indexed citations breakdown →
16.
Chaudhari, Umesh, Harshal Nemade, Vilas Wagh, et al.. (2015). Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Archives of Toxicology. 90(11). 2763–2777. 75 indexed citations
17.
Kereiakes, Dean J., Jennifer G. Robinson, Christopher P. Cannon, et al.. (2015). Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. American Heart Journal. 169(6). 906–915.e13. 291 indexed citations breakdown →
18.
19.
Rodrigues, Robim M., Joery De Kock, Mathieu Vinken, et al.. (2013). Human Skin-Derived Stem Cells as a Novel Cell Source for In Vitro Hepatotoxicity Screening of Pharmaceuticals. Stem Cells and Development. 23(1). 44–55. 47 indexed citations
20.
Stein, Linda, et al.. (2001). Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis. Journal of Cutaneous Medicine and Surgery. 5(4). 303–307. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Bolognese Breakdown of academic impact, for papers by Bernd Hohenstein Breakdown of academic impact, for papers by Peter Wijngaard Breakdown of academic impact, for papers by Agneta Siegbahn Breakdown of academic impact, for papers by Marlys L. Koschinsky Breakdown of academic impact, for papers by Michael B. Boffa Breakdown of academic impact, for papers by Marina Camera Breakdown of academic impact, for papers by Eduardo Mysler Breakdown of academic impact, for papers by Joep C. Defesche Breakdown of academic impact, for papers by Biao Xu
Rankless by CCL
2026